Wave Life Sciences Usa, Inc.
Clinical trials sponsored by Wave Life Sciences Usa, Inc., explained in plain language.
-
RNA editing drug hopes to fix genetic flaw in rare lung and liver disease
Disease control OngoingThis early-phase trial tests an experimental drug called WVE-006 in 24 people with a severe form of alpha-1 antitrypsin deficiency (Pi*ZZ). The drug is designed to edit RNA to help the body produce a working version of the protective protein. The main goal is to check safety, but…
Phase: PHASE1, PHASE2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 25, 2026 12:09 UTC
-
New hope for duchenne: Long-Term drug safety trial underway
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of an experimental drug called WVE-N531 in people with Duchenne muscular dystrophy (DMD) who have already taken it in a previous study. About 175 participants will receive the drug and be monitored for side effects, heart and lung function…
Phase: PHASE2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC